Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.
A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine. This exhaustion is influenced by immune checkpoint receptors, which are ...
Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.
T cell checkpoint modulation harnesses or inhibits natural regulatory pathways that control T cell activation, proliferation and survival. Central to this approach are inhibitory receptors such as ...
Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...
A new comprehensive review reveals that harnessing natural killer (NK) cells by blocking their “off-switches” could significantly enhance cancer immunotherapy, providing new avenues for treating solid ...
Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.
PD-L1 × TIGIT × LAG3 format enables simultaneous interrogation of three complementary checkpoint pathways within a single in ...
A study published in Cell Research advances a central idea in stem cell biology by identifying a checkpoint that controls the identity of many different types of stem cells across developmental stages ...
Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...
L1, TIGIT, and LAG3 targeting in one reagent, enabling more efficient exploration of checkpoint interactions and immune ...